title: Influence of prolonged corticosteroid therapy on the outcome of steroid-responsive nephrotic syndrome.
abstract: Eighty-six patients (59 males and 27 females) diagnosed with steroid-responsive nephrotic syndrome during childhood were identified. The patients were 20-40 years of age (mean 27.0 +/- 5.0) with a mean follow-up period of 19.5 +/- 5.9 years. All patients had been treated with a long-term tapering corticosteroid therapy. Thirty patients had also received a course of cyclophosphamide (2 mg/kg/day for 12 weeks). Sixty-six had achieved sustained remission off corticosteroids, while 20 were still receiving corticosteroids to maintain remission. None of the 86 patients had proteinuria or renal insufficiency at the time of the study. Mean final heights in males and females were similar (-0.51 +/- 1.21 and -0.23 +/- 1.16 standard deviation score). Mean final height of 20 steroid-dependent patients was significantly less than that of 66 in remission off corticosteroids (p < 0.005). Ten cyclophosphamide-treated patients got married and 9 had at least 1 healthy child. In children with steroid-responsive nephrotic syndrome, the need for corticosteroid therapy to maintain remission may be associated with decreased adult height. Patients who received a 12-week course of cyclophosphamide are likely to be normally fertile as adults.
authors.affiliation: Department of Pediatrics, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan. matsukur@ms.toyama-mpu.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Matsukura
authors.forename: S
authors.initials: S
authors.lastname: Inaba
authors.forename: K
authors.initials: K
authors.lastname: Shinozaki
authors.forename: T
authors.initials: T
authors.lastname: Yanagihara
authors.forename: M
authors.initials: M
authors.lastname: Hara
authors.forename: A
authors.initials: A
authors.lastname: Higuchi
authors.forename: T
authors.initials: T
authors.lastname: Takada
authors.forename: T
authors.initials: T
authors.lastname: Tanizawa
authors.forename: T
authors.initials: T
authors.lastname: Miyawaki
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D001827:Body Height; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology*; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D011239:Prednisolone / Q000627:therapeutic use; D012008:Recurrence; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone